Mario Sznol, MD

Professor of Medicine (Medical Oncology); Co-Director, Yale SPORE in Skin Cancer

Clinical Interests

  • Medical Oncology
  • Melanoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

General Adult Urology

Urologic Oncology Program

Yale Cancer Center: Melanoma Program | Prostate & Urologic Cancers Program

Yale Medicine

Office of Cooperative Research

Clinical Trials

Conditions Study Title
Kidney A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Melanoma, skin A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Bladder, Kidney, Lung, Melanoma, skin, Breast A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
Lung, Melanoma, skin Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Kidney, Melanoma, skin A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Colon, Melanoma, skin, Phase I An Open-Label, Multicenter, Dose Escalation and Expansion Phase 1B Study to Evaluate the Safety, Pharmacokinetics and Therapeutic Activity of RO6958688 in Combination with Atezolizumab in Patients with Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Melanoma, skin, Kidney A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors
Brain and Nervous System, Lung, Melanoma, skin A Phase II Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
Kidney, Melanoma, skin A Phase I/II, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies
Melanoma, skin A Phase II, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Lung, Melanoma, skin MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Other Skin A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Kidney Active Surveillance of the Small Renal Mass
Melanoma, skin A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Edit this profile

Contact Info

Mario Sznol, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 8

New Haven, CT 06511
View on map...
Mailing Address
PO Box 208028
333 Cedar Street

New Haven, CT 06520-8028